trastuzumab deruxtecan
Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan
Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...
JANUARY 13, 2023
Breast Cancer Drug Showing High Rates of Activity in HER2+ Gastric Cancer
A new-generation antibody drug conjugate approved for the treatment of HER2-positive breast cancer demonstrated ...
JANUARY 7, 2022
Load more